Antioxidative activity of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid.

The (-)-(1S, 3S) isomer of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid was synthesised by Pictet-Spengler condensation of tryptophan with acetaldehyde. It was evaluated for its antioxidative activity in the linoleic acid autooxidation system by the ferric thiocynate method. Butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), and alpha-tocopherol were used as the reference standards. The compound showed moderate antioxidative activity and also synergistic effect with the reference standards. The synergistic effect was in the increasing order of BHT, alpha-tocopherol and BHA. The synergistic effect was higher at higher concentrations studied.     

Decarboxylation of 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acids in brain homogenate and catalysis by pyridoxal-5'-phosphate

[Carboxyl-14C] labelled 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid (I) and 1-methyl-1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid (II) were synthesized and their decarboxylation was studied in mouse brain homogenate and buffer. The decarboxylation rates of (I) and (II) in the homogenate were about 6-fold and 4-fold, respectively, as compared with the rates in phosphate buffer. The increase could not be prevented by preheating the homogenate, but was partially abolished by addition of 1 mM EDTA. The decarboxylation was increased dose-dependently when pyridoxal-5'-phosphate was included in the buffer, 400 microM being sufficient to exceed the rate in homogenate for both (I) and (II). Mass spectrometric examination of the decarboxylation products indicated that both (I) and (II) were degraded mainly to corresponding 1,2,3,4-tetrahydro-beta-carbolines, but some 3,4-dihydro analogues also were detectable. In conclusion, the results outline a way through which these pharmacologically active beta-carbolines are readily formed under conditions that may be regarded as physiological.     

1-甲基-3-正丙基吡唑-5-甲酸乙酯的合成

目的：合成标题化合物,并进行工艺改进。方法：以2－戊酮和草酸二乙酯为原料,经三步反应合成了产物。结果：反应的总收率为47．7％。合成的各步产品经元素分析、红外和核磁共振光谱确证。结论：改进的工艺具有反应温度低、时间短等优点,并提高了收率。     

6-甲基-4-(1H)-吡啶酮-3-羧酸的制备

目的制备 6 甲基 4 (1H) 吡啶酮 3 羧酸。方法以 4 羟基 6 甲基 2 吡喃酮、N ,N 二甲基甲酰胺二甲氧基缩醛为起始原料 ,经两步反应制得目标化合物。结果与结论经熔点测定及1H NMR、MS分析确证目标产物结构 ,总收率为 39 6 % ,高于文献收率     

Synthesis and antibacterial activity of 4-benzoyl-1-methyl-5-phenyl-1H-pyrazole-3-carboxylic acid and derivatives

Some new 1H-pyrazole-3-carboxylic acid and pyridazinone derivatives were synthesized and evaluated for their antibacterial activities against Bacillus cereus ATCC 7064, Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 4230 and Pseudomonas putida using tube dilution method. The minimal inhibitory concentrations (MICs) experiments revealed that all chemical compounds showed inhibitor effects on the growth of the test microorganisms. Moreover, the results of this research showed that the compound named as 5c was the best compound in the series, exhibiting antibacterial activity against both Gram-positive and Gram-negative bacteria.     

N-aminoalkylderivatives of 1,2,3,4-tetrahydro-beta-carboline-1-spiro-4'-N'- benzylpiperidine--a putative way to novel anxiolytic agents

A series of aminoalkylderivatives of 1,2,3,4-tetrahydro-beta-carboline-1-spiro-4'-N'-benzylpiperidine were synthesized by means of chloroacetylation of the title compound and substitution of chlorine atom with various heterocyclic amines in DMSO, followed by LAH reduction of the carbonyl group. Of the ten tested compounds (4a-4e, 5a-5e), compound 5d given ip, but not orally, showed an anxiolytic activity in the four-plate test in mice and in the conflict test in rats. Compound 5d is devoid of an anticonvulsant or neurotoxic action. The activity of compound 5d resembles this of buspirone.     

1H-吲唑-3-羧酸的合成工艺改进

目的 改进1H-吲唑-3-羧酸的合成工艺.方法 以苯甲醛苯腙与草酰氯为原料得到N-亚苄基氨基-N-苯基-草氨酰氯,后者与三氯化铝反应得到关键中间体N-亚苄基氨基靛红,再经水解得到1H-吲唑-3-羧酸.结果与结论 该方法以55.3%的收率简单方便地制备了1H-吲唑-3-羧酸,所用起始原料及试剂的成本低、反应条件温和、易于操作,适合工业化生产.     

3-环己烯-1-甲酸的手性拆分研究

目的 研究外消旋3-环己烯-1-甲酸的手性拆分,获得单一构型异构体.方法 通过化学拆分法中的生成非对映异构体拆分法来拆分外消旋3-环己烯-1-甲酸,以手性苯乙胺为手性拆分剂,外消旋3-环己烯-1-甲酸在丙酮中形成非对映体异构体并利用它们的溶解度差别来进行拆分.结果 拆分为(R)-(+)-3-环己烯-1-甲酸(收率28.3％)和(S)-(-)-3-环己烯-1-甲酸(收率28.7％),光学纯度均大于99％.结论 获得外消旋3-环己烯-1-甲酸的单一构型异构体.     

Synthesis and pharmacological properties of 1-(4-substituted)butyl derivatives of amides of 7-methyl-3-phenyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimi dine-5 -carboxylic acid

The synthesis of 1-(4-substituted)butyl derivatives of amides of 7-methyl-3-phenyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimid ine-5- carboxylic acid and the results of the preliminary pharmacological screening are described in this paper. Some of them showed a weak analgesic action and caused suppression of the spontaneous locomotor activity of mice.     

Excretion,distribution and metabolism of 1,2,4-trichlorobenzene in rats

1,2,4-Trichlorobenzene (TCB) labeled with C-14 was given perorally to rats at a dosage of 50 mg/kg for excretion and distribution studies.About 66% and 17% of the oral dose was excreted in the urine and feces, respectively, within 7 days. Trapped radioactivity in the expired air amounted to 2.1% of the dose, but production of labeled carbon dioxide was negligible. Tissue residues were evenly distributed throughout the organs and tissues examined, except for the adipose tissue which consistently had a little higher concentration.The urinary, fecal and expiratory metabolites were identified. Free 2,4,5- and 2,3,5-trichlorophenol (TCP) and their conjugates were mainly detected in the urine. 5- or 6-Sulfhydryl, methylthio, methylsulfoxide and methylsulfone derivatives of TCB were also detected as minor metabolites. Dichlorobenzenes and unchanged TCB were confirmed in the expired air. Reductive dechlroination seems to be catalysed by intestinal microflora enzymes.     

Pyrrolnitrin analogues. IX. Synthesis and biological activity of 1-tolyl-3-nitrophenyl-5-methylpyrazole-4-carboxylic acids and 1-tolyl-3-methyl-5-nitrophenylpyrazole-4-carboxylic acids

The syntheses of all the possible 1-tolyl-3-nitrophenyl-5-methylpyrazole-4-carboxylic acids, 1-tolyl-3-methyl-5-nitrophenylprazole-4-carboxylic acids and of the corresponding carboxylates are reported. Several 1,3- and 1,5-diarylpyrazole derivatives were subjected to in vitro antibacterial screenings. Some acids showed activity against some strains of gram-positive bacteria. The results are discussed on the basis of structure-activity relationships.     

Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline.

14C-Labeled 1,2,3,4-tetrahydroisoquinoline (TIQ) and 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) were synthesized, and their metabolism and tissue distribution were studied. Both compounds showed similar metabolic patterns. In 24 hr after po administration (50 mg/kg) to rats, 76% of TIQ and 72% of 1MeTIQ were excreted unchanged, and 2.7 and 8.7% were excreted as the 4-hydroxyl derivatives, 4-hydroxy-TIQ and 4-hydroxy-1MeTIQ, respectively. Small amounts of N-methylated metabolites, 2-methyl-TIQ (0.4%) and 2-methyl-1MeTIQ (0.7%) were detected. Isoquinoline (2.5%) also was found as a metabolite of TIQ and 1-methyl-3,4-dihydroisoquinoline (1.0%) was found as a metabolite of 1MeTIQ. The concentration of labeled compounds in the brain was about 4.5-fold higher than the blood concentration at 4 hr after dosing, and over 90% was unchanged TIQ or 1MeTIQ. These data indicated that TIQ and 1MeTIQ easily passed through the blood-brain barrier and were concentrated in the brain. Thus, it appears that TIQ and 1MeTIQ as endogenous or exogenous amines may accumulate in the brain and may be related to the onset of Parkinson's disease.     

Investigations on the synthesis and pharmacological properties of amides of 7-methyl-3-phenyl-1-[2-hydroxy-3-(4-phenyl-1-piperazinyl)propyl]-2,4- dioxo-1,2,3,4-tetrahydropyrido[2,3-d]-pyrimidine-5-carboxylic acid

Synthesis of amides of 7-methyl-3-phenyl-2,4-dioxo-1,2,3,4- tetrahydropyrido[2,3-d]pyrimidine-5-carboxylic acid (6-10) and their 1-[2-hydroxy-3(4-phenyl-1-piperazinyl)propyl] derivatives (11-15) are described. Some of them displayed strong analgesic activity.